ISSN:
1432-0843
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Summary Fifteen patients with measurable metastatic transitional cell bladder cancer were treated with VP 16-213 100 mg/m2 IV daily for 4 days, repeated every 3 weeks. There were no complete or partial (greater than 50% reduction in area, maintained for 6 weeks) responses. Two patients showed transient reduction by 50% in the area of measurable lesions, and a further five patients showed brief stabilisation of previously progressive disease. The treatment was well tolerated. In two patients, total WBC at the nadir fell below 1.0×109/l but without complications from infection. We conclude that VP 16-213 is inactive in metastatic transitional cell urothelial cancer.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00255913